Biomarker study for trastuzumab continuation beyond progression in a randomized phase II trial of weekly paclitaxel±trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum (WJOG7112G).

Abstract

4029Background: WJOG7112G study, comparing paclitaxel plus trastuzumab (PT; n = 44) with paclitaxel alone (P; n = 45), did not demonstrate survival benefit of trastuzumab continuation beyond progre...